Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis
FM Uckun, M Saeed, M Awili, IH Ozercan… - Future …, 2022 - Taylor & Francis
Aim: Our main objectives were to compare the effects of Rejuveinix (RJX), dexamethasone
(DEX) and their combination on the severity of sepsis and survival outcome in an animal …
(DEX) and their combination on the severity of sepsis and survival outcome in an animal …
[HTML][HTML] SARS‐CoV‐2‐associated warm autoimmune haemolytic anaemia in an immunosuppressed patient: The trend continues
JW Jacobs, SD Gisriel - Transfusion Medicine (Oxford, England), 2022 - ncbi.nlm.nih.gov
Dear Editor, Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, an
increasing number of reports of haematologic sequelae secondary to severe acute …
increasing number of reports of haematologic sequelae secondary to severe acute …
[HTML][HTML] Gene Expression of TNF-α among Iraqi COVID-19 Patients with a Different Severity Status
SS Farhan, P Tahmasebi… - Medical Journal of …, 2023 - journals.lww.com
Background: Coronavirus disease 2019 (COVID-19) individuals with varied severity group
are affected by the cytokine storm brought on by SARS-CoV2 infection, which is a significant …
are affected by the cytokine storm brought on by SARS-CoV2 infection, which is a significant …
新型冠状病毒感染与糖尿病的双向关系的研究进展
谭小春， 曹莉， 潘卫 - 临床输血与检验, 2022 - lcsxyjy.com
除了引起重症肺炎外, 新型冠状病毒感染还能够引起胰腺损伤, 最终可导致糖尿病的发生,
而糖尿病又是导致新型冠状病毒肺炎恶化的风险因素之一. 因此, 新型冠状病毒感染与糖尿病之 …
而糖尿病又是导致新型冠状病毒肺炎恶化的风险因素之一. 因此, 新型冠状病毒感染与糖尿病之 …
Adjunctive Statin Therapy in Patients with Covid-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background The efficacy and safety of adjunctive statin therapy in hospitalized patients with
coronavirus disease 2019 (Covid-19) remains uncertain. Methods We systematically …
coronavirus disease 2019 (Covid-19) remains uncertain. Methods We systematically …
A COVID-19 e as citocinas: uma revisão de literatura
F Ivanski, BL Fermino… - … da Saúde da …, 2023 - unipar.openjournalsolutions.com.br
A COVID-19 surgiu em dezembro de 2019 na China, o contágio se espalhou rapidamente
pelo mundo e já em março de 2020 a Organização Mundial da Saúde (OMS) declarou o …
pelo mundo e já em março de 2020 a Organização Mundial da Saúde (OMS) declarou o …
COVID‐19 disease frequency, risk factors, and re‐infection rates in patients with autoimmune rheumatic disease receiving rituximab
B Armağan, HE Konak, B Özdemir… - … journal of rheumatic …, 2023 - Wiley Online Library
Introduction Rituximab, which is used in autoimmune rheumatic diseases (ARD), can cause
both an increased risk of development of COVID‐19 disease and re‐infection due to its …
both an increased risk of development of COVID‐19 disease and re‐infection due to its …
[HTML][HTML] Codivir suppresses SARS-Cov-2 viral replication and stabilizes clinical outcome: In vitro and Phase I clinical trial results
BACKGROUND: Treatment of severe acute respiratory distress syndrome coronavirus 2
(SARS-CoV-2) remains a significant challenge in the face of increased worldwide morbidity …
(SARS-CoV-2) remains a significant challenge in the face of increased worldwide morbidity …
The pathophysiology of COVID-19 and the cardiovascular system
N Ahsan, MO Adesida, N Memon… - COVID-19's Consequences …, 2024 - Elsevier
Several studies have shown that COVID-19 is not only a respiratory disease, but also
impacts the cardiovascular system. Many mechanisms behind cardiovascular damage …
impacts the cardiovascular system. Many mechanisms behind cardiovascular damage …
Практическая медицина
НВ СКРИПЧЕНКО, ГП ИВАНОВА… - ПРАКТИЧЕСКАЯ …, 2022 - elibrary.ru
В статье, представляющей собой литературный обзор отечественных и зарубежных
источников по проблеме иммунопатогенеза новой коронавирусной инфекции …
источников по проблеме иммунопатогенеза новой коронавирусной инфекции …